Published in Neurology on November 09, 2010
Clinical proton MR spectroscopy in central nervous system disorders. Radiology (2014) 1.53
Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease. PLoS One (2012) 1.31
Exploratory 7-Tesla magnetic resonance spectroscopy in Huntington's disease provides in vivo evidence for impaired energy metabolism. J Neurol (2011) 1.02
Brain metabolite alterations and cognitive dysfunction in early Huntington's disease. Mov Disord (2012) 0.97
Cortical metabolites as biomarkers in the R6/2 model of Huntington's disease. J Cereb Blood Flow Metab (2011) 0.91
Early white matter abnormalities, progressive brain pathology and motor deficits in a novel knock-in mouse model of Huntington's disease. Hum Mol Genet (2015) 0.87
Homeostatic adaptations in brain energy metabolism in mouse models of Huntington disease. J Cereb Blood Flow Metab (2012) 0.86
Metabolic disturbances in diseases with neurological involvement. Aging Dis (2013) 0.84
Withdrawal from long-term methamphetamine self-administration 'normalizes' neurometabolites in rhesus monkeys: a (1) H MR spectroscopy study. Addict Biol (2013) 0.83
The search for sensitive biomarkers in presymptomatic Huntington disease. J Cereb Blood Flow Metab (2012) 0.79
Aspartic acid in the hippocampus: a biomarker for postoperative cognitive dysfunction. Neural Regen Res (2014) 0.78
Neurochemical correlates of caudate atrophy in Huntington's disease. Mov Disord (2014) 0.77
Longitudinal 1H MRS of rat forebrain from infancy to adulthood reveals adolescence as a distinctive phase of neurometabolite development. NMR Biomed (2013) 0.77
N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase. Neurobiol Dis (2016) 0.76
Characterization of Behavioral, Neuropathological, Brain Metabolic and Key Molecular Changes in zQ175 Knock-In Mouse Model of Huntington's Disease. PLoS One (2016) 0.76
Thalamic metabolic abnormalities in patients with Huntington's disease measured by magnetic resonance spectroscopy. Braz J Med Biol Res (2013) 0.75
Application of ICA to realistically simulated (1)H-MRS data. Brain Behav (2015) 0.75
Imaging and spectroscopic approaches to probe brain energy metabolism dysregulation in neurodegenerative diseases. J Cereb Blood Flow Metab (2017) 0.75
Functional neuroimaging and chorea: a systematic review. J Clin Mov Disord (2017) 0.75
Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med (1993) 15.51
Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol (1985) 7.93
Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry (2007) 5.49
CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol (1997) 4.01
Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol (2009) 3.82
Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS. Magn Reson Med (1998) 2.10
Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch Neurol (1996) 1.74
Differential distribution of NAA and NAAG in human brain as determined by quantitative localized proton MRS. NMR Biomed (1997) 1.60
Magnetic resonance spectroscopy. J Neuroophthalmol (2005) 1.47
Quantitation of simulated short echo time 1H human brain spectra by LCModel and AMARES. Magn Reson Med (2004) 1.41
MRS shows abnormalities before symptoms in familial Alzheimer disease. Neurology (2006) 1.28
Studies on the distribution of N-acetyl-L-aspartic acid in brain. J Biol Chem (1957) 1.24
1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers. Neurology (1998) 1.20
Regional apparent metabolite concentrations in young adult brain measured by (1)H MR spectroscopy at 3 Tesla. J Magn Reson Imaging (2008) 1.16
Basal ganglia volume and clinical correlates in 'preclinical' Huntington's disease. J Neurol (2008) 1.15
Clinical correlation of striatal 1H MRS changes in Huntington's disease. Neurology (1999) 1.15
Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn Reson Med (1994) 1.13
Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favour of the glutamate excitotoxic theory. Mov Disord (1996) 1.06
Heterogeneity in 1H-MRS profiles of presymptomatic and early manifest Huntington's disease. Brain Res (2005) 1.06
MR image segmentation and tissue metabolite contrast in 1H spectroscopic imaging of normal and aging brain. Magn Reson Med (1999) 1.04
N-Acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntington's disease mice. Neuroreport (2000) 1.01
Decreased frontal choline and neuropsychological performance in preclinical Huntington disease. Neurology (2007) 1.00
The effect of antidepressant treatment on N-acetyl aspartate levels of medial frontal cortex in drug-free depressed patients. Prog Neuropsychopharmacol Biol Psychiatry (2005) 1.00
Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of Huntington's and Parkinson's diseases. Neurology (1998) 0.97
Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia. Alzheimers Dement (2008) 0.94
Decreased N-acetyl-aspartate/choline ratio and increased lactate in the frontal lobe of patients with Huntington's disease: a proton magnetic resonance spectroscopy study. J Neurol Neurosurg Psychiatry (1997) 0.89
Single photon emission computed tomographic blood flow and magnetic resonance volume imaging of basal ganglia in Huntington's disease. Arch Neurol (1996) 0.89
Effect of signal-to-noise ratio and spectral linewidth on metabolite quantification at 4 T. NMR Biomed (2007) 0.88
In vivo quantitative 1H MRS of cerebellum and evaluation of quantitation reproducibility by simulation of different levels of noise and spectral resolution. Magn Reson Imaging (2004) 0.88
MR spectroscopy in diagnosis and neurological decision-making. Semin Neurol (2008) 0.87
1H magnetic resonance spectroscopy in preclinical Huntington disease. Brain Res (2007) 0.86
Creatine supplementation lowers brain glutamate levels in Huntington's disease. J Neurol (2005) 0.86
Decreased brain N-acetylaspartate in Huntington's disease. Brain Res (1992) 0.85
Evidence of thalamic dysfunction in Huntington disease by proton magnetic resonance spectroscopy. Mov Disord (2007) 0.83
Proton MRS in Huntington's disease. Lancet (1994) 0.81
MR-spectroscopic findings in juvenile-onset Huntington's disease. Mov Disord (2008) 0.80
Magnetic resonance spectroscopy. Epilepsia (1996) 0.79
Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet (1999) 7.30
The psychological consequences of predictive testing for Huntington's disease. Canadian Collaborative Study of Predictive Testing. N Engl J Med (1992) 5.51
Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science (2001) 5.28
Induction of neurogenesis in the neocortex of adult mice. Nature (2000) 5.04
A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet (2004) 4.73
Biochemical basis of DNA replication fidelity. Crit Rev Biochem Mol Biol (1993) 4.69
A highly polymorphic locus very tightly linked to the Huntington's disease gene. Nature (1988) 3.90
A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat Genet (2001) 3.59
A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron (1999) 3.50
Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell (1995) 3.45
CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology (2012) 3.12
Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat Genet (1996) 3.08
Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am J Hum Genet (1996) 2.88
The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet (1997) 2.84
Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin Pharmacol Ther (2013) 2.70
A one-hit model of cell death in inherited neuronal degenerations. Nature (2000) 2.65
Predictive testing for Huntington disease in Canada: the experience of those receiving an increased risk. Am J Med Genet (1992) 2.53
Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat Genet (1998) 2.42
Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. Am J Hum Genet (2004) 2.33
Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther (2008) 2.31
Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem (1998) 2.23
Characterization and organization of DNA sequences adjacent to the human telomere associated repeat (TTAGGG)n. Nucleic Acids Res (1990) 2.23
Deletion of Huntington's disease-linked G8 (D4S10) locus in Wolf-Hirschhorn syndrome. Nature (1985) 2.19
Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations. Clin Genet (2007) 2.15
A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease. Am J Hum Genet (1999) 2.12
Clinical markers of early disease in persons near onset of Huntington's disease. Neurology (2001) 2.11
An actin-binding protein of the Sla2/Huntingtin interacting protein 1 family is a novel component of clathrin-coated pits and vesicles. J Cell Biol (1999) 2.10
HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain. Nat Genet (1997) 2.09
Rapid cell-surface prion protein conversion revealed using a novel cell system. Nat Commun (2011) 2.04
Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet (1999) 2.02
Proteome-based plasma biomarkers for Alzheimer's disease. Brain (2006) 1.98
Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. J Clin Invest (2000) 1.98
A CCG repeat polymorphism adjacent to the CAG repeat in the Huntington disease gene: implications for diagnostic accuracy and predictive testing. Hum Mol Genet (1994) 1.97
Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci (2000) 1.92
Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice. Diabetologia (2010) 1.87
The influence of huntingtin protein size on nuclear localization and cellular toxicity. J Cell Biol (1998) 1.87
Contribution of DNA sequence and CAG size to mutation frequencies of intermediate alleles for Huntington disease: evidence from single sperm analyses. Hum Mol Genet (1997) 1.82
Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J Biol Chem (2000) 1.79
Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins. Mol Psychiatry (2003) 1.79
Cell death attenuation by 'Usurpin', a mammalian DED-caspase homologue that precludes caspase-8 recruitment and activation by the CD-95 (Fas, APO-1) receptor complex. Cell Death Differ (1998) 1.76
NMDA receptor function in mouse models of Huntington disease. J Neurosci Res (2001) 1.76
Opinion: predictive testing for Huntington disease in childhood: challenges and implications. Am J Hum Genet (1990) 1.75
Tapping linked to function and structure in premanifest and symptomatic Huntington disease. Neurology (2010) 1.74
Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary artery disease. Circulation (2001) 1.71
First-trimester prenatal diagnosis for Huntington's disease with DNA probes. Lancet (1987) 1.70
Kennedy's disease: caspase cleavage of the androgen receptor is a crucial event in cytotoxicity. J Neurochem (1999) 1.66
Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr Blood Cancer (2013) 1.65
Lipoprotein lipase activity is associated with severity of angina pectoris. REGRESS Study Group. Circulation (2000) 1.65
Evidence from family studies that the gene causing Huntington disease is telomeric to D4S95 and D4S90. Am J Hum Genet (1989) 1.64
Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis. J Lipid Res (2001) 1.62
Acoustic cavitation generated by an extracorporeal shockwave lithotripter. Ultrasound Med Biol (1987) 1.61
DNA polymorphisms in and around the Apo-A1-CIII genes and genetic hyperlipidemias. Am J Hum Genet (1987) 1.61
Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J (2011) 1.60
Identification of the human cytochrome P450, P450RAI-2, which is predominantly expressed in the adult cerebellum and is responsible for all-trans-retinoic acid metabolism. Proc Natl Acad Sci U S A (2000) 1.60
Diagnosis of Huntington disease: a model for the stages of psychological response based on experience of a predictive testing program. Am J Med Genet (1993) 1.59
Predictive, pre-natal and diagnostic genetic testing for Huntington's disease: the experience in Canada from 1987 to 2000. Clin Genet (2003) 1.58
Increased instability of intermediate alleles in families with sporadic Huntington disease compared to similar sized intermediate alleles in the general population. Hum Mol Genet (1995) 1.55
HIP1 functions in clathrin-mediated endocytosis through binding to clathrin and adaptor protein 2. J Biol Chem (2001) 1.54
Identification of an oculomotor biomarker of preclinical Huntington disease. Neurology (2006) 1.52
The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis. Proc Natl Acad Sci U S A (2001) 1.51
Dirty-appearing white matter in multiple sclerosis: preliminary observations of myelin phospholipid and axonal loss. J Neurol (2008) 1.51
Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. J Biol Chem (1996) 1.47
Genetic linkage between Huntington disease and the D4S10 locus in South African families: further evidence against non-allelic heterogeneity. Hum Genet (1991) 1.46
Predictive testing for Huntington disease: II. Demographic characteristics, life-style patterns, attitudes, and psychosocial assessments of the first fifty-one test candidates. Am J Med Genet (1989) 1.46
Enzymes work by solvation substitution rather than by desolvation. Proc Natl Acad Sci U S A (1989) 1.45
Communicating pharmacogenetic research results to breastfeeding mothers taking codeine: a pilot study of perceptions and benefits. Clin Pharmacol Ther (2010) 1.44
The pharmacokinetics of ciclazindol (Wy 23409) in human volunteers. Br J Clin Pharmacol (1977) 1.44
Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. Cell Death Differ (2004) 1.44
Sex-dependent mechanisms for expansions and contractions of the CAG repeat on affected Huntington disease chromosomes. Am J Hum Genet (1995) 1.43
A somatic cell hybrid panel for localizing DNA segments near the Huntington's disease gene. Genomics (1987) 1.42
A major insertion accounts for a significant proportion of mutations underlying human lipoprotein lipase deficiency. Proc Natl Acad Sci U S A (1989) 1.41
Perinatal and first year follow-up of patients with Prader-Willi syndrome: normal size of hands and feet. Clin Genet (1989) 1.41
Sporadic inclusion body myositis not linked to prion protein codon 129 methionine homozygosity. Neurology (2000) 1.40
Measurement of mutational flow implies both a high new-mutation rate for Huntington disease and substantial underascertainment of late-onset cases. Am J Hum Genet (2001) 1.39
A PCR method for accurate assessment of trinucleotide repeat expansion in Huntington disease. Hum Mol Genet (1993) 1.39
George Huntington: the man behind the eponym. J Med Genet (1993) 1.39
Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. Am J Hum Genet (2000) 1.38
The impact of establishing a local-enhanced service for treating sexually transmitted infections in primary care. Sex Transm Infect (2008) 1.37
Positron emission tomography in the early diagnosis of Huntington's disease. Neurology (1986) 1.33
Apolipoprotein B gene variants are involved in the determination of serum cholesterol levels: a study in normo- and hyperlipidaemic individuals. Atherosclerosis (1987) 1.32
Partial gene duplication involving exon-Alu interchange results in lipoprotein lipase deficiency. Am J Hum Genet (1990) 1.31
Predictive testing for Huntington disease: interpretation and significance of intermediate alleles. Clin Genet (2006) 1.29
Human ABCA1 BAC transgenic mice show increased high density lipoprotein cholesterol and ApoAI-dependent efflux stimulated by an internal promoter containing liver X receptor response elements in intron 1. J Biol Chem (2001) 1.28
Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy. J Mol Cell Cardiol (1996) 1.27
High incidence rate and absent family histories in one quarter of patients newly diagnosed with Huntington disease in British Columbia. Clin Genet (2001) 1.26
Psychological consequences and predictors of adverse events in the first 5 years after predictive testing for Huntington's disease. Clin Genet (2003) 1.26
Social perspectives in Huntington's chorea. S Afr Med J (1980) 1.26
Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers. Clin Pharmacol Ther (2012) 1.23
Different options for prenatal testing for Huntington's disease using DNA probes. J Med Genet (1989) 1.22